REGISTER
Eli Lilly/Innovent Next-Generation BTK Inhibitor Approved for New Indication in China
Pirtobrutinib, Eli Lilly’s non-covalent BTK inhibitor introduced in China by Innovent, has been approved for adults with previously treated CLL/SLL after at least one systemic therapy including a BTK inhibitor, marking the drug’s second approved indication in China.

On February 12, Eli Lilly announced that its BTK inhibitor pirtobrutinib tablets had been approved for a new indication in China, for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor.

Pirtobrutinib is a highly selective, non-covalent BTK inhibitor. By reversibly binding BTK, it retains activity in the setting of acquired resistance through the C481 mutation, provides sustained high target coverage, and avoids complications caused by off-target effects seen with other non-covalent BTK inhibitors.

The drug is a blockbuster asset that Eli Lilly acquired through its USD 8 billion purchase of Loxo Oncology in early 2019. In China, Innovent Biologics reached a collaboration with Eli Lilly in December 2024 to introduce the import, sales, promotion, and distribution rights for pirtobrutinib in mainland China.

Insight database shows that pirtobrutinib was first approved in the United States in January 2023 and was subsequently approved in major markets including the European Union and Japan. It is currently approved in two malignancies: third-line treatment for relapsed or refractory mantle cell lymphoma (MCL), and second- and third-line treatment for CLL/SLL.

In China, pirtobrutinib was first approved in October 2024 for third-line treatment of MCL. It was successfully included in the National Reimbursement Drug List during the 2025 reimbursement negotiations, benefiting a broader group of patients. This latest approval is the drug’s second indication in China.

BRUIN CLL-321 (NCT04666038/CTR20212373) is a randomized, parallel-group, open-label global multicenter Phase III study enrolling 238 subjects, who were randomized to pirtobrutinib or investigator’s choice of IdelaR (idelalisib plus rituximab) or BR (bendamustine plus rituximab). The primary endpoint was IRC-assessed progression-free survival.

Results showed a progression-free survival hazard ratio of 0.54 ([95% CI, 0.39 - 0.75]; P = .0002). Median PFS was 14 months (95% CI, 11.2 - 16.6) in the pirtobrutinib group and 8.7 months (95% CI, 8.1 - 10.4) in the control group.

At ESMO Asia 2025, Eli Lilly released data from the Chinese subgroup of this trial. As of December 16, 2024, median IRC-assessed PFS had not been reached in the pirtobrutinib group (n=19), whereas it was 10.64 months in the control group (n=21), with an HR of 0.281 (95% CI, 0.070-1.125).

BTK inhibitors command a very large market. Starting with ibrutinib from Johnson & Johnson/AbbVie, the target has already produced three blockbuster drugs and, together with rapidly growing later entrants, more than USD 10 billion in annual global sales.

At the same time, BTK inhibitors are beginning to emerge not only in oncology but also in autoimmune disease, with regulatory approvals starting to arrive from 2025 onward.

As the first non-covalent, reversible BTK inhibitor, Eli Lilly’s pirtobrutinib has already confirmed its therapeutic potential through multiple head-to-head Phase III studies against earlier-generation agents, and it continues to expand into additional hematologic malignancies while moving into earlier lines of treatment. Pirtobrutinib generated USD 337 million in revenue in 2024 and USD 506 million in 2025, maintaining rapid growth.

Beyond oncology, pirtobrutinib has also started to expand into autoimmune indications. In December 2024, it launched its first autoimmune disease trial, a Phase I/II study in adults with immune thrombocytopenia.

Competition at this target is also fierce. According to Insight database, eight BTK inhibitors have already been approved globally, two are under regulatory review, and seven are in Phase III development. In addition to companies led by Eli Lilly that are developing non-covalent BTK inhibitors, BeiGene is also developing the BTK PROTAC drug catadegbrutinib and has already advanced it rapidly into Phase III clinical development.

0
0
Loading